Blood Cancer Treatment: SMART101 After Stem Cell Transplant

We are studying the safety and effectiveness of SMART101 for patients with blood cancers after stem cell transplantation. The goal is to see if it helps improve immune recovery and reduce complications.

>2 years11-15 visitsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInjectionHematologyInfectious Diseases

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ex Vivo Expanded Autologous Human Corneal Epithelial Cells Containing Stem Cells
Patient's own corneal cells grown outside the body that contain stem cells are used to restore and repair a damaged corneal surface, improving vision.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Smart101
Mobilized Peripheral Blood-Derived
Allogeneic T-Cell Precursors

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Institut Paoli Calmettes
Departement d'Hematologie
Marseille, France
Hospices Civils De Lyon
Departement d'Hematologie
Oullins, France
Oncopole Claudius Regaud
Departement d'Hematologie
Portet-sur-Garonne, France
Sponsor: Smart Immune
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.